AlphAIAlphAI — Financial news for AI agents
timothysykes.comSEP 243 min read$TWST

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

Original reporting
timothysykes.com
Published Sep 24, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike — source image
Source · timothysykes.com
Decision brief

The 30-second read

$TWSTBullishMed
01

Why it matters

The partnership and target hike provide a concrete, time‑sensitive catalyst that could sustain the recent price surge.

02

Market read

A fresh pharma‑AI contract and analyst upgrade are primary drivers of TWST's 16% jump, offering short‑term trading opportunities.

03

What to watch

Potential regulatory scrutiny of AI‑driven drug discovery and execution risk of scaling the Lilly deal.

Relevance 7/10Novelty 7/10Timing: today

Background

Twist Bioscience reported strong earnings earlier, but the article focuses on a new Lilly AI partnership and an analyst target raise, which are fresh catalysts.

Company-level read

Ticker impact

$TWSTBullishHigh confidence
Context

Twist Bioscience announced a new partnership with Eli Lilly's AI/ML platform TuneLab and received an analyst price‑target increase, driving a 16% intraday jump.

Expected impact

Expect continued upside if the partnership scales, with potential 5‑10% further rally in the short term.

Evidence & confidence

A fresh, material contract with a major pharma and an analyst upgrade are primary catalysts that have not been previously reported.

Market effects

Sector

Strengthens the AI‑biotech niche and may lift peer biotech stocks leveraging AI platforms.

Regional

U.S. biotech sector gains momentum; no direct regional effect beyond U.S. markets.

Global

Highlights growing pharma‑AI collaborations, relevant to global biotech investors.

Counterpoint

What could challenge this read

High cash burn and steep valuation could limit upside if partnership revenue materializes slower than expected.

Key entities

  • Company
    Twist Bioscience

    US‑listed biotech (NASDAQ: TWST) providing DNA synthesis and antibody services.

  • Company
    Eli Lilly

    Pharma partner launching the TuneLab AI platform.

  • Analyst
    Leerink Partners

    Raised TWST price target to $160, reinforcing bullish view.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Shares Soar 10.27% to New High, Extending a Remarkable 493% Yearlong Rally Fueled by AI

Twist Bioscience Corp. shares rose 10.27% to $174.78, extending a 493% yearlong rally. The surge follows a data-services agreement with Eli Lilly's AI-driven drug discovery platform, TuneLab. The company raised full-year revenue guidance to $456M-$457M and aims for adjusted EBITDA breakeven by Q4. Despite strong growth, Twist remains unprofitable with a negative EBIT margin of 31.5%.

ibtimes.com.au2 min
SEP 19
$TWSTHigh

TWST Jumps As Twist Bioscience Lands Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 7.1% following a deal with Eli Lilly for AI-driven drug discovery. Analysts see strong short-term momentum, with price targets at $160 (Leerink) and $144 (UBS). The company has high revenue growth but remains unprofitable, with Q3 free cash flow at -$8.6M. Balance sheet is stable, with a current ratio of 2.7.

timothysykes.com2 min